Compare MTEK & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MTEK | PHIO |
|---|---|---|
| Founded | 2008 | 2003 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6M | 13.5M |
| IPO Year | N/A | 2011 |
| Metric | MTEK | PHIO |
|---|---|---|
| Price | $1.62 | $1.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.67 |
| AVG Volume (30 Days) | ★ 1.3M | 667.1K |
| Earning Date | 01-01-0001 | 06-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.03 | $0.81 |
| 52 Week High | $4.27 | $4.19 |
| Indicator | MTEK | PHIO |
|---|---|---|
| Relative Strength Index (RSI) | 43.67 | 55.32 |
| Support Level | $1.48 | $1.01 |
| Resistance Level | $1.57 | $1.43 |
| Average True Range (ATR) | 0.24 | 0.08 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 8.93 | 85.58 |
Maris Tech Ltd is a business-to-business approach, or B2B provider of remote video, audio, telemetry acquisition, distribution, and sharing solutions and products, using high-end digital video, audio, and wireless communication technologies. It designs, develops, manufactures and commercially sells miniature intelligent video and audio surveillance and communication systems, which are offered as products and solutions for the professional as well as the civilian and home security markets.
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.